# Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

> **NCT03381768** · PHASE1 · COMPLETED · sponsor: **Lars Møller Pedersen** · enrollment: 8 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** PD-L2 peptide
- **BIOLOGICAL:** PD-L2 and PD-L1 peptide

## Key facts

- **NCT ID:** NCT03381768
- **Lead sponsor:** Lars Møller Pedersen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-12
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381768, "Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03381768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*